Aevi Genomic Medicine (NASDAQ:GNMX) shares traded -4.91% down during most recent session to reach at the closing price of $0.21. The stock exchanged hands 1.07 Million shares versus average trading capacity of 2.48 Million shares, yielding a market cap of $13.41 Million. Wall Street analysts covering the stock are projecting that the stock will reach $4.58 within the next 52-weeks. The mean target projections are based on 3 opinions.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have Aevi Genomic Medicine (NASDAQ:GNMX) high price target of $7 and with a conservative view have low price target of $1.75.
Jefferies “Downgrades” Aevi Genomic Medicine (NASDAQ:GNMX) in a research note issued to investors on 3/21/17 to Hold with price target of $2.5.
On the other hand the company has Relative Strength Index (RSI 14) of 49.05 along with Average True Range (ATR 14) of 0.02, Consequently Aevi Genomic Medicine (NASDAQ:GNMX)’s weekly and monthly volatility is 12.36%, 10.18% respectively. The company’s beta value is at 0.31.
In terms of Buy, Sell or Hold recommendations, Aevi Genomic Medicine (NASDAQ:GNMX) has analysts’ mean recommendation of 2.3. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
According to analysts Aevi Genomic Medicine (NASDAQ:GNMX)’s minimum EPS for the current quarter is at $-0.16 and can go high up to $-0.15. The consensus mean EPS for the current quarter is at $-0.16 derived from a total of 3 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.22 earnings per share for the same quarter during last year.
Previously Aevi Genomic Medicine (NASDAQ:GNMX) reported $-0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.22 by $-0.01. The company posted an earnings surprise of -4.5%.
Currently Aevi Genomic Medicine (NASDAQ:GNMX)’s shares owned by insiders are 0.1%, whereas shares owned by institutional owners are 19.1%. However the six-month change in the insider ownership was recorded 107.07%, as well as three-month change in the institutional ownership was recorded -3.04%.
Aevi Genomic Medicine (NASDAQ:GNMX)’s trailing twelve month revenues are $0, whereas its price to sales ratio for the same period is 0. Its book value per share for the most recent quarter is $0.22 while its price to book ratio for the same period is 0.96, as for as the company’s cash per share for the most recent quarter is $0.31, however its price to cash per share ratio for the same period is 0.68. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.